The Association of Corporate Counsel (ACC) is the world's largest organization serving the professional and business interests of attorneys who practice in the legal departments of corporations, associations, nonprofits and other private-sector organizations around the globe.
ACC Member Portal and Web Services are back online
ACC's member portal and web services are available following a scheduled upgrade. However, our team is monitoring and resolving issues promptly. Please be sure to reset your password here.
Thank you for your patience. Please contact our team with any questions.
Managed care and value-based reimbursement models are fast becoming the norm for payors and providers. Please join us for a webinar discussing some of the key managed care contracting terms for brick-and-mortar and digital health services from the perspectives of a payor and a provider. Topics will include what to look out for when preparing or reviewing a payor participation agreement, including unilateral amendments, prohibition against balance billing, incorporating provider manuals, credentialing standards, post-termination continuity of care services, and accessing and owning data.
Companies providing services to health insurers, self-funded health plans, and employers offering health benefits to employees should be aware of the potential need to obtain state licenses for certain activities. Please join us for a webinar about state law licensing requirements and what it means to health plan service providers. Topics will include the activities that may trigger licensing requirements, legal requirements for licenses, application requirements, and other related issues.
On January 5th, the Federal Trade Commission (FTC) proposed a regulation that would ban virtually all forms of employee noncompete agreements across the country. Please join us for a webinar about the FTC’s proposed rule and what it means for healthcare organizations. Topics will include what the proposed rule would mean for mergers and acquisitions, whether it may apply to nonprofit organizations, and the potential for court challenges to the proposed rule.
Same same, but different. Using case studies we will discuss the FDA’s position on interchangeable biosimilars and what it means to be “highly similar” and have “no clinically meaningful differences”.